tert-butyl (R)-3-((1-aminoisoquinolin-6-yl)oxy)piperidine-1-carboxylate | 1268605-42-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: tert-butyl (R)-3-((1-aminoisoquinolin-6-yl)oxy)piperidine-1-carboxylate
• CAS: 1268605-42-0
• 化学式: C₁₉H₂₅N₃O₃
• 分子量: 343.426
• InChiKey: DTGJPUUYKFUNJB-OAHLLOKOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  25.0
• 可旋转键数：
  2.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  77.68
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  tert-butyl (R)-3-((1-aminoisoquinolin-6-yl)oxy)piperidine-1-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 6-[(3R)-piperidin-3-yl]oxyisoquinolin-1-amine
  参考文献：
  名称：

  Fragment-based discovery of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors

  摘要：

  Fragment-based NMR screening of a small literature focused library led to identification of a historical thrombin/FactorXa building block, 17A, that was found to be a ROCK-I inhibitor. In the absence of an X-ray structure, fragment growth afforded 6-substituted isoquinolin-1-amine derivatives which were profiled in the primary ROCK-I IMAP assay. Compounds 23A and 23E were selected as fragment optimized hits for further profiling. Compound 23A has similar ROCK-1 affinity, potency and cell based efficacy to the first generation ROCK inhibitors, however, it has a superior PK profile in C57 mouse. Compound 23E demonstrates the feasibility of improving ROCK-1 affinity, potency and cell based efficacy for the series, however, it has a poor PK profile relative to 23A. (C) 2010 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2010.11.060
• 作为产物：
  描述：

  (R)-1-N-Boc-3-甲烷磺酰氧基哌啶 、 1-aminoisoquinolin-6-ol 在 PS-BEMP 作用下， 以 乙腈 为溶剂， 生成 tert-butyl (R)-3-((1-aminoisoquinolin-6-yl)oxy)piperidine-1-carboxylate
  参考文献：
  名称：

  Fragment-based discovery of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors

  摘要：

  Fragment-based NMR screening of a small literature focused library led to identification of a historical thrombin/FactorXa building block, 17A, that was found to be a ROCK-I inhibitor. In the absence of an X-ray structure, fragment growth afforded 6-substituted isoquinolin-1-amine derivatives which were profiled in the primary ROCK-I IMAP assay. Compounds 23A and 23E were selected as fragment optimized hits for further profiling. Compound 23A has similar ROCK-1 affinity, potency and cell based efficacy to the first generation ROCK inhibitors, however, it has a superior PK profile in C57 mouse. Compound 23E demonstrates the feasibility of improving ROCK-1 affinity, potency and cell based efficacy for the series, however, it has a poor PK profile relative to 23A. (C) 2010 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2010.11.060